VENOUS THROMBOEMBOLISM MARKET ANALYSIS

Market News

Key Developments

1. Major market players are focused on various business strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in May 2019, Pfizer, Inc. received the U.S. Food and Drugs Administration approval for FRAGMIN, a dalteparin sodium to reduce recurrence of venous thromboembolism (VTE) in pediatric patients, aged 1 month and above.
2. Key market players are focused on various growth strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in June 2017, Portola Pharmaceuticals, a U.S.-based biotechnology company, received the U.S. FDA approval for Bevyxxa (betrixaban), which is indicated for prophylaxis of venous thromboembolism (VTE).
3. Key players in the market are involved in various strategies such as research and development, in order to provide novel products in the market. For instance, in July 2019, Bayer AG and Johnson and Johnson’s JNJ subsidiary announced new results from phase III EINSTEIN-Jr study children suffering from venous thromboembolism (VTE).